1. Home
  2. Media
  3. News
  4. Bioiberica expands its dermatological range and launches Atopivet® Mousse and Atopivet® Oral suspension for dogs and cats

Bioiberica expands its dermatological range and launches Atopivet® Mousse and Atopivet® Oral suspension for dogs and cats

14 Sep 2020
Companion Animal Health
  • This completes its Atopivet® range of dermatological products, both orally and topically, which help maintain the skin's integrity and protective barrier
  • There is increasing evidence that shows that the epidermal barrier function is impaired in canine atopic dermatitis

Dermatological problems in canines are one of the most common reasons for veterinary clinic visits, and some experts place the prevalence of canine atopic dermatitis between 10% and 15% of the total dog population. There is increasing evidence that the epidermal barrier function is impaired in canine atopic dermatitis, confirming the need to act on the skin barrier with specific products.

Bioiberica Companion Animal Health, company specialising in dermo-repair, announces the market launches Atopivet® Mousse and Atopivet® oral suspension, two new products in its dermatological range Atopivet®.

Atopivet® maintains the integrity and protective barrier of the skin internally and externally thanks to its composition based on innovative ingredients, with scientific, effective, and safe evidence. It consists of four products: two for oral administration (capsules and oral suspension, based on nucleotides and hyaluronic acid) and two for topical administration (lotion and mousse, based on sphingolipids and hyaluronic acid).

Atopivet® capsules and Atopivet® oral suspension help to maintain the skin's protective barrier, providing nutrients for the correct development of the immune system, encouraging the migration and proliferation of fibroblasts, and providing a high EPA and DHA content.

Atopivet® Lotion and Atopivet® Mousse act by maintaining the integrity of the skin, increasing the endogenous synthesis of lipids and specifically the levels of ceramides among other sphingolipids and promoting the expression of filaggrin, essential for the stratum corneum. It also improves skin hydration and nutrition, helping to maintain the skin's protective barrier.

"The idea of this innovative range of products is to reach the different levels of the epidermis and dermis of dogs and cats with atopic dermatitis by combining ingredients of animal origin developed by Bioiberica, with a lipid profile more suitable for the endogenous synthesis of ceramides than other compounds that have a vegetable origin", explains Alfonso Velasco, director of Bioiberica Companion Animal Health.

To discuss the topic further, Tuesday 22 September at 2:30 p.m. Bioiberica is organising a webinar, “The Epidermal Barrier: a Key Element in Canine Atopic Dermatitis", with Lluis Ferrer, doctor of Veterinary Medicine and Professor of Animal Medicine and Surgery at the Universitat Autònoma de Barcelona (registration here).

Bioiberica is a worldwide leader in the life sciences sector, committed to improving the health and well-being of people, animals, and plants. The Companion Animal Health business unit specialises in innovative, science-based solutions to improve the health of chronically ill pets.